A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Study identifier:D419NC00001

ClinicalTrials.gov identifier:NCT02671435

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects with Select Advanced Solid Tumors

Medical condition

Advanced Solid Tumors

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Monalizumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Cetuximab, Cetuximab, Cetuximab, Cetuximab, Cetuximab, mFOLFOX6, mFOLFOX6, Bevacizumab

Sex

All

Enrollment

383

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 22 Feb 2016
Primary Completion Date: 26 Oct 2021
Estimated Study Completion Date: 29 Jun 2023

Study design

Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2022 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria